AUROPHARMA

Aurobindo Pharma Share Price

₹1,262.45 +9.5 (0.76%)

25 Dec, 2024 00:30

SIP TrendupStart SIP in AUROPHARMA

Start SIP

Performance

  • Low
  • ₹1,246
  • High
  • ₹1,269
  • 52 Week Low
  • ₹959
  • 52 Week High
  • ₹1,592
  • Open Price₹1,259
  • Previous Close₹1,253
  • Volume565,044

Investment Returns

  • Over 1 Month + 3.17%
  • Over 3 Month -14.75%
  • Over 6 Month + 1.72%
  • Over 1 Year + 18.38%
SIP Lightning

Smart Investing Starts Here Start SIP with Aurobindo Pharma for Steady Growth!

Invest Now

Aurobindo Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 20.5
  • PEG Ratio
  • 0.4
  • Market Cap Cr
  • 73,323
  • P/B Ratio
  • 2.5
  • Average True Range
  • 32.88
  • EPS
  • 62.24
  • Dividend Yield
  • 0.1
  • MACD Signal
  • -25.01
  • RSI
  • 50.05
  • MFI
  • 44.01

Aurobindo Pharma Financials

Aurobindo Pharma Technicals

EMA & SMA

Current Price
₹1,262.45
+ 9.5 (0.76%)
pointer
  • stock-down_img
  • Bullish Moving Average 9
  • stock-up_img
  • Bearish Moving Average 7
  • 20 Day
  • ₹1,250.88
  • 50 Day
  • ₹1,302.72
  • 100 Day
  • ₹1,332.31
  • 200 Day
  • ₹1,279.34

Resistance and Support

1259.28 Pivot Speed
  • R3 1,295.07
  • R2 1,282.08
  • R1 1,272.27
  • S1 1,249.47
  • S2 1,236.48
  • S3 1,226.67

What's your outlook on Aurobindo Pharma?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Aurobindo Pharma Ltd., is a global pharmaceutical company specializing in generic and specialty pharmaceuticals. With 25 global facilities, it operates across key therapeutic areas, including antibiotics, cardiovascular, and anti-diabetics.

Aurobindo Pharma has an operating revenue of Rs. 30,295.02 Cr. on a trailing 12-month basis. An annual revenue growth of 18% is outstanding, Pre-tax margin of 15% is great, ROE of 10% is good. The company has a reasonable debt to equity of 7%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 52 which is a POOR score indicating inconsistency in earnings, a RS Rating of 41 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 48 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Aurobindo Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-09 Quarterly Results
2024-08-10 Quarterly Results
2024-07-18 Buy Back of Shares To consider buyback for equity shares per share(175%)Second Interim Dividend
2024-05-25 Audited Results
2024-02-10 Quarterly Results & Interim Dividend
Date Purpose Remarks
2024-02-20 INTERIM Rs.1.50 per share(150%)Second Interim Dividend
2023-11-20 INTERIM Rs.3.00 per share(300%)First Interim Dividend
2023-02-17 INTERIM Rs.3.00 per share(300%)Interim Dividend
2022-06-07 INTERIM Rs.4.50 per share (450%) Fourth Interim Dividend
2022-02-21 INTERIM Rs.1.50 per share(150%)Third Interim Dividend

Aurobindo Pharma F&O

Aurobindo Pharma Shareholding Pattern

51.82%
18.53%
4.66%
16.59%
0.07%
5.33%
3%

About Aurobindo Pharma

  • NSE Symbol
  • AUROPHARMA
  • BSE Symbol
  • 524804
  • ISIN
  • INE406A01037

Similar Stocks to Aurobindo Pharma

Aurobindo Pharma FAQs

Aurobindo Pharma share price is ₹1,262 As on 25 December, 2024 | 00:16

The Market Cap of Aurobindo Pharma is ₹73323.3 Cr As on 25 December, 2024 | 00:16

The P/E ratio of Aurobindo Pharma is 20.5 As on 25 December, 2024 | 00:16

The PB ratio of Aurobindo Pharma is 2.5 As on 25 December, 2024 | 00:16

Aurobindo Pharma has an operating revenue of Rs.24,010.31 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 30% is great. Many brokers and analysts have recommended 'Buy' on the stock.

Aurobindo Pharma Ltd. has declared 40 dividends since May 10, 2000.

The stock price CAGR of Aurobindo Pharma for 10 Years is 30%, 5 Years is 0%, 3 Years is -3%, 1 Year is -25%.

Aurobindo Pharma has an ROE of 24% which is exceptional.

Aurobindo Pharma has a reasonable debt to equity of 1%, which signals a healthy balance sheet.

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23